INCY Stock Analysis: Buy, Sell, or Hold?
INCY - Incyte Genomics Inc
$108.54
4.13 (3.96%)
▲
5d:
+8.81%
30d:
+11.71%
90d:
+19.77%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.2/10
Get Alerted When INCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INCY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INCY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$179.72
Based on 11.0% avg growth
INTRINSIC VALUE TODAY
$111.59
2.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INCY is currently trading at $108.53, which is considered extended relative to its 30-day fair value range of $95.78 to $104.35. The stock's valuation (Forward PE: 11.5) is in line with its historical norms (11.8). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 83.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INCY is in a strong uptrend. The price is approaching resistance at $110.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INCY is in a strong uptrend. The price is approaching resistance at $110.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$95.78 -
$104.35
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
51.0%
Protect Your Profits
Holding INCY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- NEUTRAL: Near Wall St target ($109.35)
Trading Range Analysis
30-Day Trading Range
$95.78 -
$104.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$96.09
Resistance Level
$110.34
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.49
Wall Street Target
$109.35
(+4.7%)
Revenue Growth (YoY)
20.9%
Earnings Growth (YoY)
83.8%
Profit Margin
26.7%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
11.5 vs 11.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$103.56
(-1%)
2-Year Target
$102.74
(-2%)
3-Year Target
$101.91
(-2%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$104.64
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 18.0%)
$324.74
(+211%)
Base:
(SPY PE: 11.5, Growth: 18.0%)
$171.36
(+64%)
Bear:
(PE: 9.8, Growth: 18.0%)
$145.66
(+40%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.64 | Current EPS (TTM): $7.08
Bull Case
$146.30
(+40%)
Analyst growth 28.3%, PE expands to 16.1
Base Case
$133.00
(+27%)
Market implied 28.3%, PE stable at 14.6
Bear Case
$70.49
(-33%)
Severe decline -20.0%, PE contracts to 12.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.5 to 11.8
Stabilization Target:
$107.19
(+2.7%)
PE Expansion Potential:
+2.7%
Share & Embed Analysis
Last updated: June 24, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCY showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Pablo J Cagnoni
SELL
18667 shares
2026-04-17
Ro Khanna
BUY
2026-03-30
Pablo J Cagnoni
SELL
18667 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced INCY Option Strategies
Professional options setups generated by AI based on today's INCY price and gamma walls.
